They are adding more patients if anyone is interested.

Lpath reported interim results in a Phase 2a single-arm, open-label trial where Asonep is being investigated as a treatment for metastatic renal cell carcinoma in patients that have failed at least one therapy involving a VEGF inhibitor and no more than one mTOR inhibitor, with a maximum of three failed treatments in all. Asonep has a favorable safety profile thus far. Of the "lower-dose" patients, 7 had progressive disease at or before the end of four months; 8 were progression-free at the four-month mark and 2 exited the study due to SAEs unrelated to the drug prior to the four-month mark. The next 9 patients were initiated at a dose of 24 mg/kg. Of the higher-dose patients, 4 had progressive disease at or before the end of four months; 2 were progression-free at the four-month mark and 3 have not yet reached their four-month mark. Extending the study to a second cohort will enable Lpath to confirm the preliminary results seen to date.